Lumateperone

Lumateperone

• CAS Number: 313368-91-1
• UNSPSC Description: Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used for the study of schizophrenia and bipolar depression[1][2][3].
• Target Antigen: 5-HT Receptor; Dopamine Receptor
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Cancer; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/lumateperone.html
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: CN1C2=C3C([C@@]4([H])[C@@](CCN(C4)CCCC(C5=CC=C(C=C5)F)=O)([H])N3CC1)=CC=C2
• Molecular Weight: 393.50
• References & Citations: [1]Lumateperone|[2]Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011.|[3]J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched